Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this randomized phase II trial is to evaluate the clinical benefits
of the addition of atezolizumab to standard chemoradiotherapy (CRT) (first given concurrently
with CRT, then continued as adjuvant treatment), compared with CRT alone, on
investigator-assessed progression-free survival (PFS), as per Response Evaluation Criteria in
Solid Tumors version 1.1 (RECIST v1.1).